Eli Lilly is planning to seek another regulatory approval for Taltz after the medication hit the primary and secondary endpoints in a Phase III study for non-radiographic axial spondyloarthritis.
Shares in Solid Biosciences Inc. plunged 71 percent after a clinical trial testing the company’s gene therapy for a muscle-wasting disorder was halted for the second time in less than two years.
AstraZeneca Plc’s experimental treatment anifrolumab significantly reduced disease activity in patients with the autoimmune disorder lupus in a late-stage study.
Tokyo-based Daiichi Sankyo’s ESAX-DN Phase III trial of esaxerenone met the primary endpoint in diabetic nephropathy.
A little more than one year after Pfizer terminated the company’s studies of PF-06252616 as a potential treatment for Duchenne muscular dystrophy, Swiss pharma giant Roche is following suit with the terminated development of RG6206.
A team of Abbott scientists identified a new subtype of the human immunodeficiency virus, called HIV-1 Group M, subtype L.
A clinical trial fell short of producing statistical evidence that Novartis’ anti-inflammatory drug Cosentyx can beat the world’s best-selling medicine Humira in treating a type of arthritis.
For Breast Cancer Awareness Month, BioSpace gathered examples of recent breakthroughs in breast cancer treatment.
U.S. regulators halted a trial of Novartis’ Zolgensma treatment after an animal study raised safety concerns, in a setback for the drugmaker’s plan to expand the product’s use to older patients.